Le Lézard
Classified in: Health, Science and technology
Subject: Funding

Juvenescence Closes $100 Million Series B Round, Plans Follow on and Incremental Investments in Longevity Drug Development


Juvenescence, a life sciences company utilising expert drug developers and artificial intelligence experts to create therapeutics and technologies to treat diseases of aging and to increase human longevity, is pleased to announce the successful closure of its $100 million Series B round, including a total of $10 million from its founders and a further $10 million each from four cornerstone investors, including Grok Ventures, the investment company of Mike Cannon-Brookes (Atlassian cofounder), and Michael Spencer's private investment company, IPGL . This brings the total to $165 Million that Juvenescence has raised in 18 months and speaks to the extraordinary opportunity as well as interest in developing therapeutics with the capacity to modify aging.

Juvenescence is creating a longevity ecosystem, with world class scientists, seasoned drug developers, machine learning experts and a strong team with financial acumen to navigate this emerging new biotech growth sector and to develop 12 therapeutic candidates within the field of healthy aging.

Dr. Greg Bailey, Chief Executive Officer, commented:

"This has been such an exciting six months for Juvenescence. We have been able to add extraordinary people to the Juvenescence team who will bring our age modifying therapeutics to market. We have also augmented our team working on using machine learning for drug discovery and for drug development: culminating with closing on this $100 Million Series B financing which provides us with sufficient working capital to progress many of our programs to their initial inflection points".

Jim Mellon, Chair of Juvenescence, commented:

"We have recruited a group of sophisticated shareholders from around the world to further our common mission of improving human healthy lifespan. Juvenescence has now raised more money that any comparable company, which is testament to the depth of our team and the range of opportunities that we have assembled, in partnership with scientist/entrepreneurs and research institutions. As the science of longevity becomes mainstream, we expect significant investor interest and at some point, we anticipate taking Juvenescence public to further accelerate our development."

About Juvenescence Ltd.

Juvenescence Limited is a life sciences company developing therapies to increase healthy human longevity. It was founded by Jim Mellon, Dr. Greg Bailey and Dr. Declan Doogan. The Juvenescence team are highly experienced drug developers, entrepreneurs and investors with a significant history of success in the life sciences sector. Juvenescence will create, partner with or invest in new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures to develop therapeutics for longevity. Juvenescence believes that recent advances in science have greatly improved our understanding of the biology of aging and seeks to develop therapeutics with the possibility of slowing, halting or potentially reversing elements of aging.


These press releases may also interest you

at 13:15
Health Canada is advising Canadians that RW Consumer Products Ltd. is recalling all lots of the product "Gripe Water ? Alcohol And Preservative Free" (Natural Product Number [NPN] 80080669), sold under various brand names, because company testing...

at 13:00
ImPACT Applications, a worldwide leader in concussion management software, and Player's Health, a risk management firm specializing in amateur sports, announced a partnership to provide concussion testing protocols that will help sports organizations...

at 13:00
The CEO of Little Rock, AR-based Tree of Life Seeds, Jason Martin, has been frustrated for years with the challenges of marketing CBD. CBD, which is short for cannabidiol, is a chemical compound that comes from the cannabis plant. Jason knew that...

at 10:05
A Houston pathologist has been recognized for her pioneering work in providing free cancer screening for Latina women who don't have access to the health care system. The College of American Pathologists Foundation honored Dina R. Mody, MD, FCAP,...

at 09:34
WHO:  Humber River Hospital WHAT:  Humber River Hospital will be hosting a Community Open House on Saturday, September 21st from 10 am ? 1 p.m. and invites members of the community to attend.  Visitors will have an opportunity to tour our Hospital...

at 04:00
StatLab Medical Products is pleased to announce the receipt of patent No. 10,329,623, a novel method for development of an improved tissue-like control created by Dr. S. Ashraf Imam, Director of Advanced Diagnostics Research and Development at...



News published on 19 august 2019 at 02:05 and distributed by: